

Cover Story
FreeHealth Equity
By Matthew Bin Han Ong
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
In Brief


Clinical Roundup


Trending Stories
- In the Headlines: What’s in Trump’s draft budget?
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same
- NCI summarizes changes to the CCSG NOFO